

Webinar 3—Bibliography

- Abraham O, Myers MN, Brothers AL, et al. Assessing need for pharmacist involvement to improve care coordination for patients on LAI antipsychotics transitioning from hospital to home: A work system approach. *Res Social Adm Pharm.* 2017;13(5):1004–1013.
- American Pharmacists Association. Medication administration services. APhA website. www.pharmacist.com/medication-administration-services. Accessed July 2020.
- Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. *JAMA Psychiatry.* 2015;72(8):830–839.
- Birchwood M, Todd P, Jackson C. Early intervention in psychosis: the critical period hypothesis. *Br J Psychiatry Suppl.* 1998;172(33):53–59.
- Brissos S, Veguilla MR, Taylor D, Balanzá-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. *Ther Adv Psychopharmacol.* 2014;4(5):198–219.
- Citrome L. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. *Expert Rev Clin Pharmacol.* 2016;9(2):169–186.
- Citrome L. Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications. *Expert Rev Neurother.* 2017;17(10):1029–1043.
- Citrome L. New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. *Expert Rev Neurother.* 2013;13(7):767–783.
- Citrome L. Paliperidone palmitate—review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. *Int J Clin Pract.* 2010;64(2):216–239.
- Citrome L. Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection. *Patient Prefer Adherence.* 2009;3:345–355.
- Citrome L. Sustained-release risperidone via subcutaneous injection: a systematic review of RBP-7000 (PERSERIS™) for the treatment of schizophrenia. *Clin Schizophr Relat Psychoses.* 2018;12(3):130–141.
- Corrigan P. How stigma interferes with mental health care. *Am Psychol.* 2004;59(7):614–625.
- Ehret MJ, Davis E, Luttrell SE, Clark C. Aripiprazole lauroxil nanocrystal dispersion technology (Aristada Initio®). *Clin Schizophr Relat Psychoses.* 2018;12(2):92–96.
- Fu DJ, Turkoz I, Simonson RB, et al. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. *J Clin Psychiatry.* 2015;76(3):253–262.
- Gardner KN, Nasrallah HA. Managing first-episode psychosis: rationale and evidence for nonstandard first-line treatments for schizophrenia. *Curr Psychiatry.* 2015;14(7):33–45.
- Jagdeo A, Cox BJ, Stein MB, Sareen J. Negative attitudes toward help seeking for mental illness in 2 population-based surveys from the United States and Canada. *Can J Psychiatry.* 2009;54(11):757–766.
- Joint Commission of Pharmacy Practitioners. Pharmacists' patient care process. May 29, 2014. JCPP website. <https://jcpp.net/wp-content/uploads/2016/03/PatientCareProcess-with-supporting-organizations.pdf>. Accessed July 2020.
- Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. *Am J Psychiatry.* 2003;160(6):1125–1132.
- Kane JM, Peters-Strickland T, Baker RA, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. *J Clin Psychiatry.* 2014;75(11):1254–1260.
- Laffont CM, Gomeni R, Zheng B, et al. Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone. *J Clin Pharmacol.* 2015;55(1):93–103.

- Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. *Am J Psychiatry*. 2004;161(2 Suppl):1–56.
- Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. *J Clin Psychiatry*. 1996;57 Suppl 11:68–71.
- Lieberman JA, Sheitman BB, Kinon BJ. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. *Neuropsychopharmacology*. 1997;17(4):205–229.
- Lin C, Strauss R, Hong J, et al. Impact of a pharmacist-administered long-acting injectable antipsychotic service in a supermarket-based community pharmacy on medication adherence. *J Am Coll Clin Pharm*. 2019;2(4):343–348.
- Meltzer HY, Risinger R, Nasrallah HA, et al. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. *J Clin Psychiatry*. 2015;76(8):1085–1090.
- Missouri Society of Health Systems Pharmacists. Best practice spotlight: psychiatric long-acting injectable clinic. March/April 2019 newsletter. <http://moshp.com/blog/7236202>. Accessed July 2020.
- Mooney EV, Hamper JG, Willis RT, et al. Evaluating patient satisfaction with pharmacist-administered long-acting injectable antipsychotics in the community pharmacy. *J Am Pharm Assoc (2003)*. 2018;58(4S):S24–S29.
- Nasser AF, Greenwald MK, Vince B, et al. Sustained-release buprenorphine (RBP-6000) blocks the effects of opioid challenge with hydromorphone in subjects with opioid use disorder. *J Clin Psychopharmacol*. 2016;36(1):18–26.
- National Alliance of State Pharmacy Associations. Pharmacist authority to administer long-acting antipsychotics. Updated November 2019. NASPA website. <https://naspa.us/wp-content/uploads/2017/07/Pharmacists-Authority-to-Administer-Medications.pdf#page=2&zoom=auto,-91,539>. Accessed July 2020.
- Pharmacists as front-line responders for COVID-19 patient care. March 20, 2020. APhA website. https://www.pharmacist.com/sites/default/files/files/APHA%20Meeting%20Update/PHARMACISTS_COVID19-Final-3-20-20.pdf. Accessed July 2020.
- Skelton JB, Rothholz MC, Vatanka P. Report of the APhA stakeholder conference on improving patient access to injectable medications. *J Am Pharm Assoc*. 2017;57(4):E1–E12.
- Ziller EC, Anderson NJ, Coburn AF. Access to rural mental health services: service use and out-of-pocket costs. *J Rural Health*. 2010;26(3):214–224.